Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The New Economics of DTC: Responsibility Sells

This article was originally published in RPM Report

Executive Summary

The pharmaceutical industry's new serious tone in direct-to-consumer advertising is having an unexpected effect: commercial success. While some drug categories -- like erectile dysfunction -- may be more difficult to advertise, some marketers are finding that operating within the new voluntary guidelines makes for a more effective marketing message.

You may also be interested in...



Gottlieb Tells Brand Firms To Sell Samples For Generics – Or Face The Consequences

The idea could help quiet growing criticism over system gaming and high drug prices.

Clarifying "Clear, Conspicuous and Neutral": Advertisers Will Learn New DTC Standard on the Fly

FDA's new pre-review program for direct-to-consumer ads is up and running. The agency also has a working definition for the new standard governing risk information in broadcast ads: present it the same way you do the benefits.

The New Era in DTC: FDA Plans New Fees, Fines-and Creative Advice

The new FDA law marks a turning point in the relatively short history of direct-to-consumer broadcast ads. Sponsors have preserved the right to advertise, but will have to get used to following FDA's schedule-and taking FDA's advice.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS080060

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel